Cargando…

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

PURPOSE: Experimental evidence has suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors have an anti-inflammatory effect as well as a glucose-lowering effect, but this has yet to be confirmed in diabetic patients. Therefore, we examined the anti-inflammatory effects of two kinds of DPP-4 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teragawa, Hiroki, Morimoto, Takeshi, Fujii, Yuichi, Ueda, Tomohiro, Sakuma, Mio, Shimabukuro, Michio, Arasaki, Osamu, Node, Koichi, Nomiyama, Takashi, Ueda, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751594/ https://www.ncbi.nlm.nih.gov/pubmed/33364803 http://dx.doi.org/10.2147/DMSO.S282968

Ejemplares similares

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure
por: Yamaguchi, Satoshi, et al.
Publicado: (2019)

Prognostic Impact of Early Changes in Serum Chloride Concentrations Among Hospitalized Acute Heart Failure Patients　― A Retrospective Cohort Study ―
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Corkscrew collaterals in atherosclerosis obliterans
por: Fujii, Yuichi, et al.
Publicado: (2017)

Importance of a second spasm provocation test: Four cases with an initial negative spasm provocation test
por: Teragawa, Hiroki, et al.
Publicado: (2017)

Adrenal venous sampling in a patient with left inferior vena cava
por: Fujii, Yuichi, et al.
Publicado: (2017)

Vasospastic Angina Diagnosed by the Spasm Provocation Test with the Combined Use of the Acetylcholine and Ergonovine Provocation Tests
por: Matsumura, Mirai, et al.
Publicado: (2019)

Increased frequency of angina attacks caused by switching a brand-name vasodilator to a generic vasodilator in patients with vasospastic angina: Two case reports
por: Goto-Semba, Remi, et al.
Publicado: (2018)

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study
por: Maruhashi, Tatsuya, et al.
Publicado: (2016)

Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study
por: Teragawa, Hiroki, et al.
Publicado: (2023)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Coronary spasm: It’s common, but it’s still unsolved
por: Teragawa, Hiroki, et al.
Publicado: (2018)

The Myocardial Bridge: Potential Influences on the Coronary Artery Vasculature
por: Teragawa, Hiroki, et al.
Publicado: (2019)

The Significance of Recognizing Myocardial Bridge in the Coronary Spasm Diagnosis in Myocardial Infarction with Nonobstructive Coronary Arteries
por: Teragawa, Hiroki, et al.
Publicado: (2019)

Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients
por: Yamakawa, Ken, et al.
Publicado: (2012)

Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials
por: Nezu, Uru, et al.
Publicado: (2013)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study
por: Shimabukuro, Michio, et al.
Publicado: (2017)

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men
por: Shimabukuro, Michio, et al.
Publicado: (2016)

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
por: Tomiyama, Hirofumi, et al.
Publicado: (2016)

The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Prediction of Stroke After Cardiac Catheterization: No Reason, No Stroke
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio, Shinya, et al.
Publicado: (2015)

WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study
por: Kawabe, Atsuhiko, et al.
Publicado: (2021)

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study
por: Miwa, Yoshikazu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0is84jpivkos82rhgojffq0d4q